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Abstract
A distinct group of colorectal carcinomas (CRCs) referred to as the “CpG island
methylator phenotype” (CIMP) shows an extremely high incidence of de novo DNA
methylation and may share common pathological, clinical or molecular features.
However, there is limited consensus about which CpG islands (CGIs) define a CIMP,
particularly in microsatellite stable (MSS) carcinomas. To study this phenotype in a
systematic manner, we analyzed genome-wide CGI DNA methylation profiles of
19 MSS CRC using methyl-CpG immunoprecipitation (MCIp) and hybridization on
244K CGI oligonucleotide microarrays, determined KRAS and BRAF mutation status
and compared disease-related DNA methylation changes to chromosomal instability
as detected by microarray-based comparative genomic hybridization. Results were
validated using mass spectrometry analysis of bisulfite-converted DNA at a subset of
76 individual CGIs in 120 CRC and 43 matched normal tissue samples. Both genome-
wide profiling and CpG methylation fine mapping segregated a group of CRC
showing pronounced and frequent de novo DNA methylation of a distinct group of
CGIs that only partially overlapped with previously established classifiers. The CIMP
group defined in our study revealed significant association with colon localization,
either KRAS or BRAF mutation, and mostly minor chromosomal losses but no associ-
ation with known histopathological features. Our data provide a basis for defining
novel marker panels that may enable a more reliable classification of CIMP in all
CRCs, independently of the MS status.
Abbreviations: CGI, CpG island; CIMP, CpG island methylator phenotype; CIN, chromosomal instability; CNV, copy number variation; CRC, colorectal carcinoma; ES cells, embryonic stem cells;
GO, gene ontology; MCIp, methyl-CpG immunoprecipitation; MSI, microsatellite instable; MSS, microsatellite stable.
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What's new?
The CpG island methylator phenotype (CIMP) is an important feature of colorectal carcinoma
(CRC). No consensus exists, however, on a marker panel that defines CIMP in CRC, neither for
microsatellite stable (MSS) nor for microsatellite instable disease. Here, to better understand
associations between markers and CIMP CRC, the authors analyzed genome-wide CpG island
DNA methylation profiles in CRC. Genome-wide profiling and CpG methylation fine mapping
revealed frequent de novo DNA methylation of a group of CpG islands. The CIMP group, the
basis for a novel marker panel, was associated with colon localization, KRAS and BRAF mutation,
and minor chromosomal losses.
1 | INTRODUCTION
Carcinogenesis is generally associated with both genetic and
epigenetic alterations that likely act in concert to drive disease ini-
tiation and progression. Epigenetic lesions often include an aber-
rant redistribution of DNA methylation, resulting in global
hypomethylation and a regional hypermethylation in CpG islands
(CGIs). Whereas the former is thought to favor chromosomal insta-
bility (CIN) and the inappropriate activation of oncogenes, the
latter may lead to the permanent silencing of tumor-suppressor
genes.1 Certain tumors show an exceptionally high incidence of
CGI de novo DNA methylation (mCGI) and may constitute distinct
subclasses sharing common pathological, clinical or molecular fea-
tures. This so-called “CpG island methylator” phenotype (CIMP)
was first discovered in colorectal carcinomas (CRCs) as a class of
tumors showing frequent mCGI of several promoters and included
the majority of sporadic CRC with microsatellite instability (MSI)
related to hMLH1 methylation.2 A refined definition of CIMP
marker regions based on a larger candidate gene panel revealed
the tight association of MSI CIMP with activating mutations in the
BRAF oncogene.3 This panel of five markers was further extended
to an eight-marker panel, which allowed for comprehensive studies
of CIMP.4 However, the existence and clinical relevance of the
CIMP status have been a constant matter of debate,5 and the use
of different methods and variable marker panels to define CIMP
has led to markedly divergent estimates of CIMP frequency and its
association with other genetic markers.6 Notably, there is largely
conflicting data about the existence of CIMP in sporadic, microsat-
ellite stable (MSS) CRC, which are frequently associated with
KRAS rather than BRAF mutations.7 The selection of currently
used CIMP markers has primarily been based on candidate gene
approaches and MSI CRC8 questioning the adequacy of CIMP to
describe MSS CRC. Some studies actually provided evidence
supporting different hypermethylation profiles in genetically dif-
ferent CRCs,9 suggesting that MSS CRC may have a unique
hypermethylation signature that is poorly represented in current
marker panels.9 Due to this lack of consensus, a precise panel of
marker genes allowing a standardized identification of CIMP in all
groups of CRC remains to be defined.
Here, we performed a global analysis of aberrant DNA methyla-
tion across the large majority of human CGI for 19 sporadic MSS
CRC, identified a segregate subgroup of CIMP-positive MSS CRC
and defined a new candidate marker panel that can classify all
CIMP CRCs.
2 | MATERIALS AND METHODS
2.1 | Sample collection and processing
CRC clinical sample collection and staging, and processing of clinical
samples and control cells are described in the Supporting information.
2.2 | Sample analyses
Microsatellite analysis, KRAS and BRAF mutation analysis, methyl-
CpG immunoprecipitation (MCIp) microarray, mass spectrometry anal-
ysis of bisulfite-converted DNA (using the MassARRAY system) and
microarray-based comparative genomic hybridization (aCGH) were
performed as described in the Supporting Information.
2.3 | Statistics
All statistical testing of enrichment data (motifs or attributes) was per-
formed using a cumulative hypergeometric distribution (Fisher exact
test). Statistical testing of differences in CpG content, mRNA level and
H3K27me3 distributions was done using the two-sided Mann-Whitney
U test. Differences were considered statistically significant when
P values were < .05. Correlation between clinicopathological and molec-
ular parameters was tested using a two-sided Fisher's exact test.
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3 | RESULTS AND DISCUSSION
3.1 | Unsupervised clustering of genome-wide
DNA methylation data segregates CIMP CRC samples
To globally characterize aberrant de novo DNA methylation in CRC,
we analyzed the methylation status of 23 000 CGIs (mCGIs) of the
human genome in 19 MSS CRCs samples (compared to normal aged
colon), using MCIp coupled with microarray analysis.10 A previously
described set of 10 comparative MCIp methylation profiles11 was
extended by nine additional MSS CRC samples, and KRAS and BRAF
mutational status were determined (Tables S1 and S2).
Individual probe signals were combined to assign methylation
ratios (sample MCIp/reference MCIp) to whole CGI regions.11 As a
normal control (reference), we used colon from three healthy aged
donors (median age 59). Since we were unable to obtain DNA from
colon of healthy young donors, we could not directly study the
influence of age on DNA methylation. Hence, we also included mono-
cyte DNA of younger origin (median age 23) in our comparison. Com-
pared to monocytes, a large set of CGI (~1400) was preferentially
methylated in aged colon, whereas only a small set of genes (~100)
showed tissue-specific methylation in blood monocytes. Since colon-
specific methylation targets comprised many CGI that were previously
shown to be de novo methylated during aging,12 and the majority of
these CGI were even more strongly methylated in several CRC and
also frequently de novo methylated in primary acute leukemia samples
(Figure S1), we concluded that most of these regions (“age” group) are
prone to age-related de novo methylation in normal colon.
A hierarchical two-dimensional unsupervised clustering of
hypermethylation data was conducted to identify distinct subsets of
methylation behavior (Figure 1A). The initial set of 23 000 CGI was
reduced to CGI regions on autosomes (to exclude sex bias). Around
5000 CGI regions showed a clear MCIp enrichment in at least three inde-
























































































































































































































































































F IGURE 1 Global DNA hypermethylation data segregates CRC samples. (A) Comparative MCIp data for CpG island (CGI) regions clearly
hypermethylated (mCGI) in at least three independent samples were used for the hierarchical two-dimensional unsupervised clustering (here:
Manhattan distance and Ward's linkage rule). All tested clustering approaches separated a group of five CRC samples (CRC4, 6, 10, 12 and 17)
that were characterized by high levels of de novo DNA methylation, likely representing the CGI methylator phenotype (CIMP). As indicated below
the cluster diagram, all five samples were characterized by the presence of a KRAS mutation (red boxes). Based on the potentially age-related
origin of de novo methylation (as indicated by the hypermethylation data for normal colon), CGI regions were divided into five groups (C1-4 as
indicated and the age group). (B) Gene ontology analysis reveals strong associations of the mCGI group with developmental processes as
compared to all CGI regions (all CGI). Log10 P values (hypergeometric) for the enrichment/depletion of the indicated terms are shown (green or
red coloring of P values indicates enrichment or depletion, respectively). Separate analysis of individual subgroups (C1-C4, “age”) reveals different
compositions with the C1 group being least associated with developmental terms. Bars indicate ratios of observed vs expected term distributions,
and the numbers represent Log10 P values (hypergeometric) for the enrichment of each term
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as a separate subgroup of MSS CRC, comprising samples with the
highest frequency of de novo DNA methylation. This group was consis-
tently segregated using different hierarchical clustering approaches
(Manhattan-Ward's, Pearson centered-average and Euclidean-centroid)
and likely constitutes CIMP in MSS CRC (MSS-CIMP). The clustering
analysis also revealed four major groups of CGI (C1-C4) that showed
variable specificity, with C1 and C3 being least associated with the
“age” group and highly associated with the MSS-CIMP group. In general,
aberrant de novo methylation was a common feature of CRC.
3.2 | Aberrant silencing in CIMP CRC is mediated
by age-independent mechanisms
As observed in previous studies, genes associated with mCGI
were generally enriched for gene ontology (GO) terms related to develop-
mental processes (Figure 1B). Separate GO term analyses of the four
major CGI clusters (C1-C4, Figure 1A) as well as putative age-related de
novo methylation targets (“age” group) revealed significant differences
between these groups. The “age” group was most strongly enriched for
development-related attributes, whereas the MSS-CIMP-specific C1 clus-
ter showed the least association (Figure 1B). Among the five groups, C1
and age also differed significantly in their CpG content, mRNA expression
and ES cell H3K27 trimethylation but not so much in their CGI size
(Figure S2A-D). The “age” group had the lowest median CpG content
(Figure S2A), and neighboring genes were rarely expressed in normal
colon (Figure S2C). In addition, “age” group of CGI had the highest associ-
ation with the Polycomb group (PcG) repressor mark H3K27me3 in ES
cells (Figure S2D), in line with previous studies.13 In contrast, the MSS-
CIMP-specific C1 cluster showed average CpG content, higher mRNA
expression in normal colon and lower median H3K27me3 in ES cells
(Figure S2A-D). In addition, the C1 group comprised more promoter
regions (Figure S2E) and showed a higher evolutionary conservation com-
pared to the age group (Figure S2F). De novo motif analyses showed that
the age group was depleted for five previously identified ubiquitous tran-
scription factor motifs associated with DNA methylation protection (Sp1,
NRF1, YY1, GFY and GABP) and enriched for several cell type-specific
consensus motifs (Figure S3), suggesting that the “age” group is particu-
larly enriched for developmental and differentiation-associated genes that
are usually not expressed in colon. In contrast, the MSS-CIMP-specific
C1 cluster showed only little association with sequence motifs
(Figure S3). These differences suggest separate (yet unknown) mechanis-
tic pathways for the aberrant silencing of MSS-CIMP-specific C1 cluster
genes compared to the age-dependent methylation pathway.
3.3 | CIMP CRCs have fewer chromosomal losses
CRC is often characterized by CIN. Previous work suggested that CIMP
and CIN may represent alternative routes for cancer development,14
although a considerable overlap between CIMP and CIN has also been
shown.15 Since disease-related de novo methylation often causes gene
repression that may complement chromosomal losses or mutations, we
related DNA methylation profiles with chromosomal changes in CRC
samples. Unbalanced chromosomal changes were analyzed by aCGH
(Figure S4 and Table S3). The global distribution of copy number varia-
tion (CNV) in our CRC was comparable to that of previous studies.16
The relation of CIMP and KRAS status with losses at commonly deleted
chromosomal regions (8p23-p12, 15q11-q15, 17p13-p11 and 18) sug-
gests an association of both KRAS mutation and CIMP with the appear-
ance of fewer chromosomal losses.
3.4 | CGI methylation compensates for copy
number variation in CIMP CRCs
Since DNA methylation may participate in compensating chromosomal
gains,17 we globally related the distribution of MCIp enrichment with copy
number alterations. As a prime example for dosage compensation, the dis-
tribution of methylation (MCIp signal) ratios in male and female X-
chromosomes was compared to that observed across all chromosomes of
an individual (Figure S5A). In female CRC samples, dosage compensation
at one X chromosome resulted in a marked shift of methylation ratios
compared to all chromosomes. In contrast, the gain of X chromosomes in
male CRC only induced a slight increase in overall DNA methylation, likely
reflecting the copy number gain relative to the male reference sample.
Similar observations were made at autosomes with unbalanced chromo-
somal changes; in individual samples with stable diploid chromosome
8, shown as representative example, the distribution of methylation ratios
was similar to that of all other chromosomes, whereas samples with chro-
mosome 8p deletions and 8q amplifications showed a corresponding loss
or gain of methylation in the respective regions relative to all other chro-
mosomes (Figure S5B). Both methylation gains and losses roughly cor-
responded to relative copy number changes, suggesting that the
mechanisms responsible for aberrant DNA methylation in individual sam-
ples are largely independent of chromosome copy numbers.
3.5 | A new marker panel identifies CIMP CRCs
better than previous known markers
To validate our microarray analysis and to test potential marker regions
using an independent approach, we selected a set of 83 regions for mass
spectrometry analysis of bisulfite-converted DNA (MassARRAY) from
CRC samples and matched normal colon tissue. The set comprised a num-
ber of previous marker regions (literature set), representative examples of
C2, C3, C4 and age group (validation set) as well as a panel of MSS-CIMP-
specific C1 cluster regions (novel CIMP candidate set). Seven regions were
excluded due to poor quality spectra. For the remaining 76 amplicons,
mean methylation ratios of individual regions obtained by the MassARRAY
and MCIp microarray approaches were highly concordant (median Pear-
son coefficient of .81). To validate previous and novel candidate markers
for CIMP, we analyzed an additional set of CRCs, so that we had in total a
number of 120 CRC (102 MSS CRCs, 10 MSI CRCs and the MS status of
8 patients was not available) together with 43 matched normal colon tis-
sues and 11 samples of healthy human blood monocytes.
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Unsupervised hierarchical clustering for the 76 selected regions
(Figure 2) revealed with few exceptions that the validation set (labeled
in black) clearly segregated normal tissues (monocytes and colon) and
cancer samples. Most of these regions (except the top rows in the
cluster analysis which represent regions with colon-specific DNA
methylation) include potential biomarkers for cancer, showing low
levels or absent DNA methylation in all control samples and a high
penetrance of aberrant methylation frequency in CRC.
The newly defined marker regions that constitute our novel CIMP
candidate panel (labeled in red) clearly segregated the CIMP samples,
including those five samples previously detected by the comparative
MCIp approach. This novel candidate marker panel enabled a better
distinction than established CIMP markers from the literature (labeled
in green) (Figure S6).
3.6 | CIMP CRCs are associated with KRAS or
BRAF mutations and colon localization
The descriptive analyses of CIMP, clinical and histopathological
parameters revealed a CIMP frequency of 19.2% (23/120) in our
whole CRC cohort. The presence of CIMP was significantly associated
with tumor localization (preferentially in the left and right sided colon;
P = .0015) and either KRAS or BRAF V600E mutation status
(P < .001), but not with age, sex, histologic grade, lymph node metas-
tasis, lymphatic or venous invasion (Table 1). The observation that
CIMP in our cohort of CRC correlated with either KRAS or BRAF
mutation, which belong to one same pathway, suggests that this
genetic defect is directly linked to the yet unknown mechanisms
responsible for CIMP aberrant DNA methylation profile. Global profil-
ing studies as well as studies focusing on defined CIMP marker panels
have identified similar genotype/epigenotype relationships.18-22
Although our new CIMP marker panel was defined based on MSS
CRC, all BRAF-mutated MSI CRC were also detected as hyper-
methylated. Thus, our new marker panel did not only segregate hyper-
methylated MSS CRC (13/23) but also hypermethylated MSI CRC
(8/23). Our data, therefore, suggest that traditional markers may
underestimate the frequency of CIMP and that our novel candidate
marker panel could help to reach a consensus on how to score CIMP
in all subgroups of CRC. Accordingly, previous studies have also








F IGURE 2 Hierarchical clustering of regional DNA methylation data obtained by MALDI-TOF MS. CGI regions selected for validation
purposes from the C2, C3, C4 and age group (labeled in black), candidates for a refined CIMP panel (C1 cluster regions, labeled in red) as well as
previously defined CIMP markers (labeled in green) were analyzed using bisulfite conversion and subsequent MALDI-TOF MS in 120 CRC
samples and 54 normal controls (including 40 matched normal colon tissues, 3 normal colon samples from healthy donors and 11 samples of
human blood monocytes). Mean methylation ratios were subjected to hierarchical two-dimensional unsupervised clustering (Manhattan distance
and Ward's linkage rule). DNA methylation values are depicted by a color scale as indicated (methylation ranges from yellow [0 = non-
methylated] to red [1 = fully methylated]). Sample characteristics including KRAS, BRAF and MSI/MSS status as well as tissue type are
represented in color-coded rows below the diagrams (red: mutated; gray: not determined)
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TABLE 1 Clinicopathological and molecular characteristics of MSS CRC in relation to CIMP
Group Negative Positive P Test statistic Effect size (CI)
Observations 97 23
Age
Median (MAD) 66.00 (11.86) 71.00 (7.41) .13 0.27 0.37 (0.83; 0.097)
Mean (SD) 64.79% (11.66) 68.87% (8.64)
Range 37-90 52-87
Missing 1.0% (1) 0.0% (0)
Tumor localization
Colon 28% (27) 65% (15) .0015 9.4 0.21 (0.07; 0.61)
Rectum/sigma 70% (68) 35% (8)
Missing 2.1% (2) 0% (0)
Gender
F 31% (30) 43% (10) .33 0.76 0.59 (0.21; 1.7)
M 68% (66) 57% (13)
Missing 1% (1) 0% (0)
Lymphnode.metastases
pN0 59% (57) 74% (17) .24 1.2 0.51 (0.15; 1.5)
pN1-2 41% (40) 26% (6)
Missing 0% (0) 0% (0)
Lymphatic.invasion
L0 14% (14) 22% (5) .43 0.25 0.44 (0.036; 3.3)
L1 13% (13) 8.7% (2)
Missing 72% (70) 70% (16)
Venous.invasion
V0 22% (21) 30% (7) .3 0.9 0 (0; 2.8)
V1 7.2% (7) 0% (0)
Missing 71% (69) 70% (16)
Tumor stage
pT2 14% (14) 4.3% (1) .3 1 3.9 (0.53; 172)
pT3-5 81% (79) 96% (22)
Missing 4.1% (4) 0% (0)
KRAS
Mut 28% (27) 43% (10) .14 1.6 0.49 (0.17; 1.4)
Wt 69% (67) 52% (12)
Missing 3.1% (3) 4.3% (1)
BRAF
Mut 3.1% (3) 48% (11) <.001 33 0.034 (0.0053; 0.16)
Wt 95% (92) 48% (11)
Missing 2.1% (2) 4.3% (1)
MS.status
MSI-H 2.1% (2) 35% (8) <.001 23 0.038 (0.0036; 0.22)
MSS 92% (89) 57% (13)
Missing 6.2% (6) 8.7% (2)
BRAF/KRAS
Mut 31% (30) 91% (21) <.001 27 0.023 (5.4e04; 0.16)
Wt 66% (64) 4.3% (1)
Missing 3.1% (3) 4.3% (1)
Notes: Values in bold correspond to statistically significant results (P value < 0.05).
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3.7 | A 10-marker methylation panel effectively
identifies all CIMP CRC patients
To facilitate clinical application of this panel, we selected a subset of
10 markers predicted to be the most informative by an ensemble of
machine learning approaches (Table S6). Indeed, this reduced panel
had the same discriminatory power as the 76 amplicons together
(Figure 3A). To validate its applicability, we used this 10-marker panel
to cluster Illumina 450K methylation array from 394 CRC patients in
The Cancer Genome Atlas (TCGA) (READ and COAD projects). CIMP
cases were defined by K-means clustering of the top 5000 most vari-
able CpG sites (Figure S7). Our novel panel, consisting of only
10 regions, achieved a 95.1% sensitivity and 99.7% specificity in the

















F IGURE 3 A 10-marker methylation panel effectively identifies CIMP patients in CRC. (A) Hierarchical clustering of in-house methylation
data from 120 CRC patients and 54 normal samples. The 10 most informative CGI regions from the original set were selected by machine
learning approaches. Mean methylation ratios of CRC patients were subjected to hierarchical two-dimensional unsupervised clustering
(Manhattan distance and Ward's linkage rule). DNA methylation values are depicted by a color scale as indicated (methylation ranges from yellow
[0 = non-methylated] to red [1 = fully methylated]). Sample characteristics are represented in color-coded rows below the diagrams (red:
mutated; gray: not determined). CIMP cases clustered separately as shown for the entire panel of 76 amplicons, confirming that the reduced
panel shows identical discriminatory power. (B) Hierarchical clustering of TCGA methylation data from 394 CRC patients and 45 matched normal
colon samples. Individual CpG sites contained in the regions of the CIMP panel (10-marker panel) were binned, and the average methylation
ratios were calculated. The resulting matrix was subjected to hierarchical two-dimensional unsupervised clustering as described in (A)
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4 | CONCLUSIONS AND FUTURE
PERSPECTIVES
It remains unclear, whether defects on the level of genotype or
epigenotype co-evolve during clonal selection of cancer cells, or
whether one is the consequence of the other. We and others showed
that CGIs that are usually protected against de novo methylation are
characterized by the combinatorial binding of transcription factors or
RNA polymerase II, suggesting that disturbances of transcriptional
networks frequently observed in cancer cells may have a profound
impact on the cancer epigenome.11,24 This is further supported by stud-
ies showing that genes involved in chromatin remodeling are prevalently
mutated in CIMP CRC.18,25 On the other hand, overexpression of BRAF
mutant in a CIMP-negative and BRAF-wild-type colon carcinoma cell
line failed to induce CIMP, suggesting that the signals provided by BRAF
mutant may not be sufficient for the induction of CIMP.26
The exact mechanism underlying CIMP remains elusive.15 Clearly,
further studies are needed to clarify whether DNA hypermethylation
events are a cause or a consequence of CRC development. Our new
marker panel could provide a novel basis to define CIMP, regardless
of the MSI/MSS status, and might aid future investigations to define
the frequency and role of CIMP in CRC.
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